Search for a trial

Varenicline, a partial nicotinic receptor agonist, for the treatment of excessive daytime sleepiness in Parkinson*s disease: a placebo-controlled cross-over study

This study is aimed to determine the efficacy of varenicline in reducing EDS in PD patients.

An outpatient phase 3 efficacy study of Ecopipam (PSYRX 101) in the symptomatic treatment of self-injurious behavior in subjects with Lesch-Nyhan disease.

The primary objective of this study is to assess the efficacy of Ecopipam to reduce self-injurious behaviors (SIB) in adults and children with Lesch-Nyhan Disease (LND) in an outpatient setting. The secondary objectives of this study are to assess…

A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double
Dummy Extension Study of Preladenant in Subjects With Moderate
to Severe Parkinson*s Disease

This is a active-controlled dose-range-finding study which is also designed to assess the efficacy and safety of preladenant 2, 5, 10 mg twice daily during long term use as an adjunct therapy to L-dopa when administered to subjects with moderate to…

Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson's disease patients with motor complications not well controlled on medical treatment.

The primary objective of the trial is to investigate the efficacy of apomorphine subcutaneous infusion compared to placebo in PD patients with motor fluctuations not well controlled on medical treatment. The secondary objective is to investigate the…

RANDOMISED DOUBLE BLIND 12-MONTH STUDY OF PREGABALINE FOR PATIENTS WITH RESTLESS LEGS

Primary• To assess the efficacy of a fixed dose of pregabalin to placebo during the first12-week treatment period in subjects with RLS.• To compare the rate of augmentation of a fixed dose of pregabalin to 2 fixed doses ofpramipexole over 9 or 12…

A Phase 3, 12-Week, Double-Blind, Placebo- and Active-Controlled, Double Dummy
Efficacy and Safety Study of Preladenant in Subjects with Moderate
to Severe Parkinson*s Disease.

This is a placebo- and active-controlled dose-range-finding study which isalso designed to assess the efficacy and safety of preladenant 2, 5, 10 mg twicedaily versus placebo as an adjunct therapy to L-dopa when administered to subjectswith moderate…

Dopamine-serotonin dysbalance and the relation to myoclonus and psychiatric co-morbidity in patients with dystonia

To investigate if jerks and psychiatric disorders in patients with dystonia are associated with a hyperdopaminergic/ hyposerotonergic system and whether reversal of a hyposerotonergic state has a therapeutic effect.

Randomised multicentre trial comparing bilateral subthalamic nucleus DBS and bilateral globus pallidus internus DBS for advanced Parkinson*s disease

We hypothesize that bilateral globus pallidus internus (GPi) DBS produces greater functional improvement in PD than bilateral STN DBS because of a lower rate of complications.

A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson*s disease experiencing motor fluctuations (BouNDless)

Primary ObjectiveThe primary objective of the study is to determine the effect of ND0612 on daily *ON* time without troublesome dyskinesia (defined as the sum of "ON" time without dyskinesia and *ON* time with non-troublesome dyskinesia)…

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active
Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety.

Main objective:To demonstrate superior efficacy with evobrutinib compared to Teriflunomide in terms of Annualized Relapse Rate (ARR) Secondary objectives:a.To demonstrate the efficacy of evobrutinib relative to that of Teriflunomide on disability…

A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST HUNTINGTON'S DISEASE

The primary efficacy objective for this study is to evaluate the efficacy of RO7234292 compared with placebo.The secondary efficacy objective for this study is to evaluate the efficacy of RO7234292 compared with placebo.The safety objective for this…